Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer

Cancer Medicine

Volumn 5, Issue 8, 2016, Pages 1873-1882

  Kurozumi, Sasagu ^a,d   Yamaguchi, Yuri ^a   Hayashi, Shin ichi ^b   Hiyoshi, Hiromi ^c   Suda, Tetsuji ^a   Gohno, Tatsuyuki ^b   Matsumoto, Hiroshi ^a   Takei, Hiroyuki ^a   Horiguchi, Jun ^d   Takeyoshi, Izumi ^d   Oyama, Tetsunari ^d   Kurosumi, Masafumi ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; carboxyl terminus of the Hsc70 interacting protein (CHIP); postmenopausal patients; prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEAT SHOCK COGNATE PROTEIN 70; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SURVIVAL TIME;

EID: 85000716950     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.780     Document Type: Article

References (35)

1. Ballinger, C. A., P. Connell, Y. Wu, Z. Hu, L. J. Thompson, L. Y. Yin, et al. 1999. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell Biol. 19:4535–4545.
2. Connell, P., C. A. Ballinger, J. Jiang, Y. Wu, L. J. Thompson, J. Höhfeld, et al. 2001. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3:93–96.
3. Ahmed, S. F., S. Deb, I. Paul, A. Chatterjee, T. Mandal, U. Chatterjee, et al. 2012. The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J. Biol. Chem. 287:15996–16006.
4. Kajiro, M., R. Hirota, Y. Nakajima, K. Kawanowa, K. So-ma, I. Ito, et al. 2009. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat. Cell Biol. 11:312–339.
5. Wang, L., Y. T. Liu, R. Hao, L. Chen, Z. Chang, H. R. Wang, et al. 2011. Molecular mechanism of the negative regulation of Smad1/5 protein by carboxyl terminus of Hsc70-interacting protein (CHIP). J. Biol. Chem. 286:15883–15894.
6. Valcourt, U., M. Kowanetz, H. Niimi, C. H. Heldin, and A. Moustakas. 2005. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 16:1987–2002.
7. Ansieau, S., J. Bastid, A. Doreau, S. P. Morel, B. P. Bouchet, C. Thomas, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008; 14: 79–89.
8. Xiong, Z., and P. W. Laird. 1997. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25:2532–2534.
9. Hayashi, S., and Y. Yamaguchi. 2008. Estrogen signaling pathway and hormonal therapy. Breast Cancer 15:256–261.
10. Anderson, E. 2002. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 4:197–201.
11. Jiang, Y., Y. E. Liu, I. D. Goldberg, and Y. E. Shi. 2004. Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis. Cancer Res. 64:4539–4546.
12. Fan, M., A. Park, and K. P. Nephew. 2005. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol. Endocrinol. 19:2901–2914.
13. Pratt, W. B., Y. Morishima, H. M. Peng, and Y. Osawa. 2010. Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp. Biol. Med. (Maywood) 235:278–289.
14. Citri, A., and Y. Yarden. 2006. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7:505–516.
15. Graus-Porta, D., R. R. Beerli, J. M. Daly, and N. E. Hynes. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1647–1655.
16. Waterman, H., and Y. Yarden. 2001. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490:142–152.
17. Song, R. X., C. J. Barnes, Z. Zhang, Y. Bao, R. Kumar, and R. J. Santen. 2004. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl. Acad. Sci. USA 101:2076–2081.
18. Jan, C. I., C. C. Yu, M. C. Hung, H. J. Harn, S. Nieh, H. S. Lee, et al. 2011. Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. J. Pathol. 225:424–437.
19. Zhou, P., N. Fernandes, I. L. Dodge, A. L. Reddi, N. Rao, H. Safran, et al. 2003. ErbB2 degradation mediated by the co-chaperone protein CHIP. J. Biol. Chem. 278:13829–13837.
20. Shiber, A., and T. Ravid. 2014. Chaperoning proteins for destruction: diverse roles of Hsp70 chaperones and their co-chaperones in targeting misfolded proteins to the proteasome. Biomolecules 4:704–724.
21. Demicheli, R., G. Bonadonna, W. J. M. Hrushesky, M. W. Retsky, and P. Valagussa. 2004. Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res. 6:R689–R696.
22. Miliaras, D., A. Kamas, and H. Kalekou. 1995. Angiogenesis in invasive breast carcinoma: is it associated with parameters of prognostic significance? Histopathology 26:165–169.
23. Marinho, A., R. Soares, J. Ferro, M. Lacerda, and F. C. Schmitt. 1997. Angiogenesis in breast cancer is related to age but not to other prognostic parameters. Pathol. Res. Pract. 193:267–273.
24. Yamaguchi, Y., H. Takei, K. Suemasu, Y. Kobayashi, M. Kurosumi, N. Harada, et al. 2005. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res. 65:4653–4662.
25. Hosoda, M., M. Yamamoto, K. Nakano, K. C. Hatanaka, E. Takakuwa, Y. Hatanaka, et al. 2014. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res. Treat. 144:249–261.
26. Wang, Y., F. Ren, Y. Wang, Y. Feng, D. Wang, B. Jia, et al. 2014. CHIP/Stub1 functions as a tumor suppressor and represses NF-kB-mediated signaling in colorectal cancer. Carcinogenesis 35:983–991.
27. Perou, C. M., T. Sorlie, M. B. Eisen, T. Hastie, J. S. Marron, A. Nobel, et al. 2000. Molecular portraits of human breast tumours. Nature 406:747–752.
28. Sorlie, T., R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, et al. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100:8418–8423.
29. Eroles, P., A. Bosch, J. A. Perez-Fidalgo, and A. Lluch. 2012. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 38:698–707.
30. Cheang, M. C., S. K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, et al. 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101:736–750.
31. Dowsett, M., T. O. Nielsen, R. A'Hern, J. Bartlett, R. C. Coombes, J. Cuzick, et al. 2011. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 103:1656–1664.
32. Goldhirsch, A., E. P. Winer, A. S. Coates, R. D. Gelber, M. Piccart-Gebhart, B. Thürlimann, et al. 2013. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24:2206–2223.
33. Paik, S., S. Shak, G. Tang, D. Gao, S. Leung, J. Snider, et al. 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351:2817–2826.
34. Tran, B., and P. L. Bedard. 2011. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 13:221.
35. Hiyoshi, H., N. Goto, M. Tsuchiya, J. Bartlett, R. C. Coombes, J. Cuzick, et al. 2014. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. Sci. Rep. 4:7095.